BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-elevar-rivoceranib-camrelizumab-hcc-pdufa-2026@catalyst-calendar.local
DTSTAMP:20260720T200621Z
DTSTART:20260723T130000Z
DTEND:20260723T133000Z
SUMMARY:Elevar/Hengrui rivoceranib+camrelizumab一线HCC NDA重提交PDUFA
DESCRIPTION:Elevar官方披露，FDA已受理rivoceranib联合camrelizumab用于一线不可切除肝细胞癌的NDA重提交，PDUFA目标日期为2026年7月23日。该事件同时影响恒瑞PD-1国际化、HCC一线竞争和中资创新药出海验证。\\nImpact score: 74\\nExpected: 关注是否解决此前CRL相关问题，以及FDA是否批准中国PD-1联合VEGF-TKI进入美国一线HCC市场。\\nAffected: HLB.KS(subject\, unknown\, score 86)\; 600276.SH(licensor\, unknown\, score 74)\; NVS(peer\, mixed\, score 34)\; IBB(etf\, mixed\, score 45)\\nSources: Elevar FDA acceptance: https://elevartx.com/2026/02/02/elevar-fda-acceptance-rivo/\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-elevar-rivoceranib-camrelizumab-hcc-pdufa-2026
CATEGORIES:fda\,US\,FDA\,PDUFA\,HCC\,camrelizumab\,China biotech
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: Elevar/Hengrui rivoceranib+camrelizumab一线HCC NDA重提交PDUFA
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: Elevar/Hengrui rivoceranib+camrelizumab一线HCC NDA重提交PDUFA
END:VALARM
END:VEVENT
END:VCALENDAR